Kodiak Sciences Inc.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, with programs aimed at conditions such as geographic atrophy and glaucoma. It is also building a digital health platform, VETi, that combines proprietary LiDAR sensing, AI and wearable imaging concepts to support its retina franchise and related applications.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational biologic therapies designed for retinal diseases such as geographic atrophy and glaucoma.
Drug candidates built on Kodiak's Antibody Biopolymer Conjugate platform for longer-durability ocular treatment.
VETi and related AI-enabled wearable headset and imaging technologies.
Internal discovery, preclinical work, clinical development and regulatory preparation.
Customers
Kodiak does not currently sell commercial products and has not generated product revenue, so its direct customers are not yet established. If approved, its therapies would be used by ophthalmologists and retina specialists treating patients with chronic retinal diseases, while any digital health products could be sold to clinical, research or other end users depending on the final application. Near term, the company’s economic counterparties are primarily regulators, clinical trial sites, CROs, manufacturers and potential collaboration partners rather than paying customers.
Would prescribe any approved retinal disease therapy for patients with GA, glaucoma or related indications.
End users of future therapies, especially patients needing durable intravitreal treatment options.
CROs, trial sites and manufacturers that enable development, testing and scale-up before approval.
Third parties that may help sell, market or distribute approved products if Kodiak outsources commercialization.
Potential users of VETi or related prototype devices in imaging, identity security or cognitive science applications.
Strategy
Kodiak’s strategy is to advance its ABC platform programs in geographic atrophy and glaucoma toward IND and eventual clinical development, aiming to create longer-durability retinal therapies than current standards of care. It is also extending its technology base through VETi and related LiDAR/AI work, which could broaden the company’s platform value beyond ophthalmology. Because it lacks a commercial infrastructure, the company may also rely on partnerships or future capital raises to fund development and eventual commercialization.
Clinical entry is the key value-creation step for a pre-commercial biotech.
Better efficacy and less frequent dosing could improve adoption versus current therapies.
Broadens the technology base and may create optionality beyond the core retina franchise.
The company needs capital and may need collaborators to reach commercialization.
Geography
Kodiak is headquartered in the United States and its disclosed business activity is centered on U.S.-based research, development and corporate operations. The company has not disclosed product revenue by geography because it has no commercial sales yet, so its geographic exposure is mainly where clinical trials, suppliers, regulators and future commercialization partners are located. As a development-stage biotech, its operating footprint is driven more by trial execution and capital markets access than by end-market sales geography.
Risks
Kodiak is a clinical-stage company with no approved products, so its value depends on successful development, regulatory clearance and eventual commercialization of its pipeline. The company also faces substantial financing risk, because it expects ongoing losses and may need to raise capital on dilutive or restrictive terms. Competitive, operational and cybersecurity risks are material because larger biopharma companies have greater resources and the company relies on complex R&D, trial execution and protected intellectual property.
- Clinical development failure or delayImpact: CriticalLikelihood: High
The company is in clinical-stage development and its programs may not reach approval.
Exposure: GA and glaucoma programs
- Financing and going-concern riskImpact: CriticalLikelihood: High
Kodiak has recurring losses, negative operating cash flow and limited cash runway.
Exposure: Need to raise additional capital in 2026 and beyond
- Commercialization execution riskImpact: HighLikelihood: Medium
The company has no sales or marketing infrastructure and may need third parties.
Exposure: Future approved products
- Competitive pressure in retinal diseaseImpact: HighLikelihood: Medium
Rivals may develop safer, more effective or more convenient therapies sooner.
Exposure: Retinal disease indications
- Cybersecurity and data protectionImpact: MediumLikelihood: Medium
Remote work and sensitive IP increase exposure to phishing, ransomware and data loss.
Exposure: Proprietary technology and confidential trial data
Accounting
Judgemental itemsClinical-stage spending is the main operating cost and drives reported losses.
Impact: Affects quarterly operating loss and cash burn visibility
Typical for biotech and can be a meaningful non-cash expense.
Impact: Impacts operating expenses and adjusted profitability comparisons
The company has funded operations partly through sale of future royalties and may enter more deals.
Impact: Could affect revenue timing, liabilities and cash flow presentation
Management disclosed substantial doubt about continuing as a going concern.
Impact: Signals financing dependence and affects risk assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
Kodiak AI, Inc.
KDK · Services-Computer Integrated Systems Design
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Kiora Pharmaceuticals, Inc
KPHMW · Pharmaceutical Preparations
Eastman Kodak Company Common New
KODK · Photographic Equipment & Supplies
MeiraGTx Holdings plc
MGTX · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease,…
Lineage Cell Therapeutics, Inc.
LCTX · Biological Products, (No Diagnostic Substances)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or off-the-shelf, cell therapies for serious ophthalmic and neurological diseases.
Last updated: 24/09/2026